Registration Open: Unlocking the Future of Healthcare Finance and Venture Capital in Beijing
The pharmaceutical and healthcare industry stands at a crossroads of transformation, with the dual drivers of population aging and technological convergence creating unprecedented development opportunities. The deep integration of biotechnology and artificial intelligence has accelerated rapid advancements in frontier fields such as new drug development and cell and gene therapy, holding promise for significantly improving global health outcomes. However, this process is also accompanied by challenges, including high R&D costs, intense market competition, capital market volatility, and policy uncertainty.
Particularly since 2023, the global healthcare financing environment has tightened, with a shrinkage in total primary market funding, highlighting the severe challenges facing the market. In China, although investment activities in the healthcare sector remain active, total funding has also declined, reflecting a broader “financing winter” across the industry. In the face of such challenges, venture capital and private equity firms need to exercise greater prudence in their investment decisions, identifying and supporting projects with genuine innovative potential and market prospects, while implementing effective risk management measures to mitigate potential risks. Furthermore, while national policy support is a crucial factor driving the high-quality development of the pharmaceutical and health industries, enterprises must also respond flexibly to policy changes and regulatory requirements to ensure long-term, stable growth.
In the development of the pharmaceutical and healthcare sector, technological innovation, market demand, policy direction, and international cooperation are often-cited pillars of industrial growth. However, what is frequently overlooked is that breakthroughs in industrial progress also depend on regions with strong cluster advantages and robust synergistic ecosystems. For pharmaceutical and healthcare companies, identifying regions and ecosystems conducive to their development is crucial. Consequently, many localities are investing resources and hosting forums and other events to attract and support these companies in exploring new pathways for growth. Amid this wave of initiatives aimed at boosting industrial development, the “Pharmaceutical and Healthcare Financial Investment Innovation Forum,” created by Chang Development Group, is an event not to be missed for the industry.
Why?Because this forum, in terms of its organizational caliber and quality, is not only delving into depth and expanding breadth, but also building an ecosystem. How should this be understood? This requires returning to the essential nature of the demands within the pharmaceutical and health industries.
Reflecting on Value Discovery: The “Healthcare Finance and Investment Innovation Forum” has been successfully held for two editions, each contributing its unique value to the development and prosperity of the industry. The inaugural forum in 2022 built an online bridge for communication within and outside the industry during the pandemic, featuring nearly 40 guests from government, academia, financial investment, and pharmaceutical and medical device innovation sectors. It attracted nearly one million online viewers, facilitating information exchange and in-depth sharing of innovative insights. The second forum in 2023 further deepened the forum’s value system by exploring greater depth, expanding breadth, and building an ecosystem.
In DepthDistinguished guests gathered for the event. Liu Juncai, Director of the Beijing Municipal Health Commission; Wu Bin, Director of the Beijing Municipal Medical Products Administration; Zhao Weijiu, Party Group Member and Deputy Director of the Beijing Municipal Local Financial Supervision and Administration Bureau; Gan Jingzhong, Secretary of the Changping District Committee of the Communist Party of China and Secretary of the Party Working Committee of Future Science City, delivered opening remarks. Zhang Xian’en, Vice Chairman of the Chinese Society for Biotechnology and Director of its Synthetic Biology Branch; Wu Yun, Director of the Beijing Stock Exchange; and Chen Youtang, Deputy Secretary-General of the Insurance Asset Management Association of China, delivered keynote speeches. Furthermore, addressing the theme of “how basic research and original innovation empower industrial development,” Gao Dapeng, Executive Director and General Manager of Joinn Laboratories; Li Qian, Chairman of Beijing Sun-Novo Pharmaceutical Research Co., Ltd.; Liu Guoen, Dean of the Institute for Global Health Development at Peking University and Academician of the Chinese Academy of Medical Sciences; and Xiao Zhi, Co-Head and Managing Director of the Life Sciences Team at SDIC Capital, provided their insights.
In terms of breadth, bringing together major factions from the “academic-research,” “financial,” and “industrial” camps to focus on the pharmaceutical and medical device industry, innovation ecosystems, and financial empowerment. VP-level guests attended, including Beijing Gaobo Hospital, the Institute for Precision Medicine at Tsinghua University, Beijing Jishuitan Hospital affiliated with Capital Medical University, BGI Blue Rainbow Life Science Accelerator, ATLATL, Shenzhen Capital Group, Changkejin, CDH Investments, Qiao Capital, Danlu Capital, Huagai Capital, Dianshi Chuangjian, Yingke Capital, Fosun Health Capital, Fortune Capital (Dachen Caizhi), Yahui Investment, BGI Win-Win, Yuanyi Capital, Yiyin Healthcare Fund, ImmuneOnco, CytoMed Therapeutics, ImmuOnco, Huapu Instrumentation, Weimai Medical, Hongrun Health, Changmugu, Jiuyiyuan, and Thermo Fisher Scientific. Standing in diverse ecological niches, they contributed thought-provoking insights grounded in frontline industry experience.
Ecologically, bringing together stakeholders from government, industry, academia, research, healthcare, and investment sectors, the event attracted precise industry professionals, including representatives from over 223 domestic investment institutions, 37 financial service institutions, and 54 universities and hospitals. In addition to providing content resources, the on-site participation helped build an ecosystem platform for resource exchange, striving to fully promote inter-industry communication, sharing, and cooperation. This initiative provides more comprehensive support and synergy for innovation in pharmaceuticals and health, practically advancing the integration of technological innovation with capital.
Following the successive interest rate cuts by the U.S. Federal Reserve and the People’s Bank of China in September 2024, the global economy has entered a new easing cycle. This significant adjustment in macroeconomic policy has not only provided fresh momentum for economic growth but also injected new vitality into the venture capital and private equity market in the healthcare and pharmaceutical sectors. Globally, the low-interest-rate environment has reduced the cost of capital, making high-risk, long-cycle R&D projects in the healthcare and pharmaceutical industries more attractive. Consequently, the healthcare and pharmaceutical VC/PE market has once again become a focal point for investors seeking stable growth and defensive investment opportunities.
A series of supportive policies introduced in China, including accelerating the new drug approval process and increasing the localization rate of medical devices, have further provided policy support for the heating up of the pharmaceutical and healthcare industry. In the next stage, the pharmaceutical and healthcare financial venture capital market is expected to remain active, driven by the heatwave in the financial market, and the strengthening of international cooperation will also bring new growth opportunities to the market. How can we further tap into the investment potential of the pharmaceutical and healthcare industry? How will the global interest rate cut trend affect the future direction of the pharmaceutical and healthcare financial venture capital market? How should investors seize the growth opportunities in this round of the pharmaceutical and healthcare industry? And how should companies leverage the current policy and market environment to accelerate innovation and internationalization?
To explore how the new phase of the industry will unfold, this event is hosted by the People's Government of Changping District, Beijing, and Beijing State-owned Capital Operation and Management Co., Ltd., and co-organized by the Administrative Committee of Future Science City (Life Science Park Administrative Committee), the Administrative Committee of Changping Park of Zhongguancun Science Park, the Development and Reform Commission of Changping District, Beijing, Beijing Changping Science Park Development Group Co., Ltd., Beijing Changke Jin Investment Co., Ltd., and Chongqing Dongmaicheng Technology Co., Ltd. (VCBeat VB100).2024 Changping Healthcare Innovative Financial Investment Forum (CHIF), will also beNovember 22, 2024Officially launched. As a highly representative brand forum for financial investment in healthcare, CHIF focuses deeply on sci-tech innovation financial investment and empowerment based on the construction of regional industrial clusters and innovative ecosystems, by building“Pharmaceuticals & Healthcare + Financial Investment Experience Sharing Platform” and “Pharmaceuticals & Healthcare Industry Linkage and Innovation Ecosystem Collaboration Platform” Dual Platforms, in the form of an annual forum, brings together top experts, scholars, entrepreneurs, and investors from China and abroad to jointly discuss frontier trends, innovative technologies, and collaborative models in the pharmaceutical and healthcare industry, as well as the pivotal role of financial investment in driving industrial upgrading.
In the process of preparing for this year’s CHIF Forum, we have consistently adhered to promoting the deep integration of the pharmaceutical and health industries with the financial investment sector, focusing on“Forging Synergy Through Industry and Finance, Quality Innovation for the Future”centered on its core theme, we have carefully curated a series of compelling agenda items and discussion topics. These initiatives not only showcase Changping District’s unique appeal and ecological advantages in the life health industry but also establish a diversified platform for exchanging ideas, sharing experiences, and exploring collaborations. Through this effort, we aim to stimulate new momentum within the industry, drive innovative development in the pharmaceutical and healthcare sectors, and jointly usher in the next phase of high-quality growth.
A Star-Studded Lineup of Guests, Jointly Mapping Out the Industry Blueprint.This edition of the CHIF Forum will bring together top scientists, clinical experts, economists, policy specialists, and industry entrepreneurs from five key sectors—government, industry, academia, investment, and empowerment—to Changping. They will jointly explore and share cutting-edge technologies, innovative applications, economic trends, and policy directions in critical fields such as biopharmaceuticals and medical devices. This cross-disciplinary lineup of distinguished guests not only lends authoritative voices and forward-looking insights to the forum but also builds a bridge for attendees to engage in direct dialogue with industry leaders.
Types of Forum Guests
Target the Right Audience, Unite Industry Strength.This edition of the CHIF Forum will leverage targeted publicity and promotion to invite innovative representatives from multiple sectors, including the pharmaceutical and health industries, investment community, academia and research institutions, and enablement service providers. The diverse audience, encompassing the entire pharmaceutical and health industry chain, will bring abundant information resources and collaboration opportunities to the forum. This will foster cross-disciplinary and cross-industry exchange and cooperation, accelerate the promotion and application of new products, technologies, and business models, and provide robust project and intellectual support for the high-quality development of Changping District’s pharmaceutical and health industry.
Forum Audience Types
Diverse Agenda Topics, Energizing the Industry.From economists’ in-depth analysis of the new logic driving economic growth in the health industry, to scientists’ cutting-edge insights on synthetic biology and innovation in bio-manufacturing, to securities analysts’ outlook on IPO trends in pharmaceuticals and healthcare, as well as discussions on “building ships to sail overseas” strategies against the backdrop of international cooperation, every segment of the forum was meticulously designed around industry hotspots and frontier trends. Furthermore, two specially curated roundtable forums—“Tracing the Origins of New Quality Productive Forces” and “Unleashing New Quality Productive Forces”—focused on source innovation in medical technology and expansion of the industrial chain. Guests shared practical, hands-on experience to stimulate innovation and vitality across the industry.
Forum Agenda Framework
Innovation is the core driver of development in the pharmaceutical and healthcare sectors, and behind every innovation lies the need for support and synergy from diverse resources. In other words, ecological integration forms the foundational backdrop of pharmaceutical and healthcare advancement. A new era focused on ecosystem convergence and collaboration is rapidly approaching. As the CHIF Forum draws near, we are filled with anticipation, confident that it will be a moment rich in inspiration and opportunity. Here, every discussion has the potential to spawn world-changing innovative ideas, and every exchange may foster cross-disciplinary collaborations. We look forward to witnessing at the CHIF Forum those insights that can lead industry transformation, those partnerships that can propel technological progress, and those investment decisions that can invigorate market vitality.
Let us look forward to November 22, 2024, when the 2024 Changping Pharmaceutical and Health Finance Investment Innovation Forum, held at the Jiuhua Villa Exhibition Hotel in Beijing, will become a historic moment—a milestone marking the Chinese pharmaceutical and health industry’s ascent to new heights. With open minds, an innovative spirit, and pragmatic action, let us embark on this exciting journey together and join hands to shape a brilliant future.
Changping Healthcare Innovative Financial Investment Forum (CHIF), held annually in Changping, has successfully hosted two editions since 2022. The 3rd Changping Healthcare Innovative Financial Investment Forum is scheduled to take place as planned on November 22, 2024.
As a highly representative brand forum for healthcare financial investment, CHIF focuses deeply on sci-tech innovation financial investment and empowerment based on regional industrial clusters and the construction of innovative ecosystems. By establishing two platforms—the “Pharmaceutical & Healthcare + Financial Investment Experience Sharing Platform” and the “Pharmaceutical & Healthcare Industry Linkage and Innovative Ecosystem Cooperation Platform”—and holding an annual forum, it brings together top domestic and international experts, scholars, entrepreneurs, and investors to jointly explore frontier trends, innovative technologies, and cooperation models in the pharmaceutical and healthcare industry, as well as the key role of financial investment in promoting industrial upgrading.
CHIF, the conference brand, is not only an acronym for Changping Healthcare Investment Forum but also embodies the enduring spirit of “Collaboration, High-Tech, Innovation, and Foresight.” Aligned with the “Healthy China” strategy, the conference will engage in in-depth discussions on new opportunities, challenges, and pathways in the pharmaceutical and health industries.
Looking ahead, CHIF will continue to serve as a bellwether in the field of pharmaceutical and healthcare financial investment, leading industry innovation and development, and contributing to the prosperity and progress of the pharmaceutical and healthcare industries in China and around the world.